Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Determination of Serum Differential Carnitine Ester Levels in HIV(+) Patients: A Cross-Sectional Study

Author(s): Irfan Binici*, Halil İbrahim Akbay, Zübeyir Huyut, Hamit Hakan Alp, Hasan Karsen, Ismail Koyuncu, Ataman Gonel, Şükrü Akmeşe and Hakim Çelik

Volume 21, Issue 1, 2023

Published on: 18 January, 2023

Page: [18 - 26] Pages: 9

DOI: 10.2174/1570162X21666221219141016

Price: $65

Abstract

Objective: It has been reported that carnitine deficiency is observed in various viral infections and in the follow-up of the prognosis of some diseases. In this cross-sectional study, we aimed to determine how carnitine ester derivatives change in HIV-positive patients.

Materials and Methods: In this study, 25 HIV-infected patients who applied to Harran University Faculty of Medicine Education Research and Practice Hospital Infectious Diseases and Clinical Microbiology Outpatient Clinic and who did not receive any antiretroviral treatment, as well as 25 healthy volunteers were included in the study. Carnitine ester levels in serum samples were measured by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) method (Shimadzu North America, Columbia, MD, USA).

Results: While suberoylcarnitine (C8DC), myristoleylcarnitine (C14:1), tetradecadienoylcarnitine (C14:2), palmitoleylcarnitine (C16:1), and linoleylcarnitine (C18:2) levels in HIV(+) patients were quite low compared to the control group, tiglylcarnitine (C5:1) levels were high (p ≤ 0.05). In addition, C5:1 and C14:2 index parameters according to VIP score, and C5:1 and C14:1/C16 index parameters according to ROC analysis were determined as markers with high potential to distinguish HIV(+) patients from healthy volunteers.

Conclusion: This study showed that levels of acylcarnitine derivatives might be altered in HIV(+) patients, and the results obtained may contribute to a better understanding of carnitine metabolism.

« Previous Next »
Graphical Abstract

[1]
Carter AL, Abney AO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol 1995; 10 (Suppl.): 283-7.
[2]
Pons R, De Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995; 10(Suppl): 2S8-2S24.
[3]
Gnoni A, Longo S, Gnoni GV, Giudetti AM. Carnitine in human muscle bioenergetics: Can carnitine supplementation improve physical exercise? Molecules 2020; 25(1): 182.
[http://dx.doi.org/10.3390/molecules25010182] [PMID: 31906370]
[4]
Bene J, Szabo A, Komlósi K, Melegh B. Mass spectrometric analysis of L-carnitine and its esters: Potential biomarkers of disturbances in carnitine homeostasis. Curr Mol Med 2020; 20(5): 336-54.
[http://dx.doi.org/10.2174/1566524019666191113120828] [PMID: 31729298]
[5]
Rezaee H, Khalili H, Salamzadeh J, Jafari S, Abdollahi A. Potential benefits of carnitine in HIV-positive patients. Future Virol 2012; 7(1): 73-83.
[http://dx.doi.org/10.2217/fvl.11.133]
[6]
Esteban-Cruciani NV. Severe carnitine deficiency in children with AIDS: Improved functional activity status after supplementation. Pediatr Res 2001; 49: 254A.
[7]
De Simone C, Tzantzoglou S, Jirillo E, Marzo A, Vullo V, Martelli EA. L-carnitine deficiency in AIDS patients. AIDS 1992; 6(2): 203-6.
[http://dx.doi.org/10.1097/00002030-199202000-00011] [PMID: 1558717]
[8]
Butorov EV. Plasma L-carnitine and L-lysine concentrations in HIV-infected patients. Open Biochem J 2017; 11(1): 119-31.
[http://dx.doi.org/10.2174/1874091X01711010119] [PMID: 29387270]
[9]
Wang S, Yang X, Liu F, et al. Comprehensive metabolomic analysis reveals dynamic metabolic reprogramming in Hep3B cells with aflatoxin B1 exposure. Toxins (Basel) 2021; 13(6): 384.
[http://dx.doi.org/10.3390/toxins13060384] [PMID: 34072178]
[10]
Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and safety of L-carnitine treatment for chronic heart failure: A meta-analysis of randomized controlled trials. BioMed Res Int 2017; 2017: 1-11.
[http://dx.doi.org/10.1155/2017/6274854] [PMID: 28497060]
[11]
Flanagan JL, Simmons PA, Vehige J, Willcox MDP, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010; 7(1): 30.
[http://dx.doi.org/10.1186/1743-7075-7-30] [PMID: 20398344]
[12]
Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l -Carnitine and heart disease. Life Sci 2018; 194: 88-97.
[http://dx.doi.org/10.1016/j.lfs.2017.12.015] [PMID: 29241711]
[13]
Kumar MA, Bitla ARB, Raju KVN, Manohar SM, Kumar VS, Narasimha SRPVL. Branched chain amino acid profile in early chronic kidney disease. Saudi J Kidney Dis Transpl 2012; 23(6): 1202-7.
[http://dx.doi.org/10.4103/1319-2442.103560] [PMID: 23168849]
[14]
Hisamatsu T, Okamoto S, Hashimoto M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One 2012; 7(1): e31131.
[http://dx.doi.org/10.1371/journal.pone.0031131] [PMID: 22303484]
[15]
Fukutake N, Ueno M, Hiraoka N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One 2015; 10(7): e0132223.
[http://dx.doi.org/10.1371/journal.pone.0132223] [PMID: 26133769]
[16]
Ravaglia G, Forti P, Maioli F, et al. Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am J Clin Nutr 2004; 80(2): 483-8.
[http://dx.doi.org/10.1093/ajcn/80.2.483] [PMID: 15277174]
[17]
Sharma S, Black SM. Carnitine homeostasis, mitochondrial function and cardiovascular disease. Drug Discov Today Dis Mech 2009; 6(1-4): e31-9.
[http://dx.doi.org/10.1016/j.ddmec.2009.02.001] [PMID: 20648231]
[18]
Liepinsh E, Kalvinsh I, Dambrova M. The Regulation of Energy Metabolism Pathways Through L-carnitine homeostasis. In (Ed), role of the adipocyte in development of type 2 diabetes IntechOpen ISBN 978-953-307-598-3.
[http://dx.doi.org/10.5772/22478]
[19]
Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C(2): 77-85.
[http://dx.doi.org/10.1002/ajmg.c.30087] [PMID: 16602102]
[20]
Wutzke KD, Lorenz H. The effect of l-carnitine on fat oxidation, protein turnover, and body composition in slightly overweight subjects. Metabolism 2004; 53(8): 1002-6.
[http://dx.doi.org/10.1016/j.metabol.2004.03.007] [PMID: 15281008]
[21]
Meyburg J, Schulze A, Kohlmueller D, Linderkamp O, Mayatepek E. Postnatal changes in neonatal acylcarnitine profile. Pediatr Res 2001; 49(1): 125-9.
[http://dx.doi.org/10.1203/00006450-200101000-00024] [PMID: 11134502]
[22]
Sayed-Ahmed MM. Role of carnitine in cancer chemotherapy-induced multiple organ toxicity. SPJ 2010; 18(4): 195-206.
[http://dx.doi.org/10.1016/j.jsps.2010.07.008]
[23]
Simone CD, Famularo G, Tzantzoglou S, Trinchieri V, Moretti S, Sorice F. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS. AIDS 1994; 8(5): 655-60.
[http://dx.doi.org/10.1097/00002030-199405000-00012] [PMID: 7914733]
[24]
Sinha A, Ma Y, Scherzer R, et al. Carnitine is associated with atherosclerotic risk and myocardial infarction in HIV‐infected adults. J Am Heart Assoc 2019; 8(9): e011037.
[http://dx.doi.org/10.1161/JAHA.118.011037] [PMID: 31030595]
[25]
Vilaseca MA, Artuch R, Sierra C, et al. Low serum carnitine in HIV-infected children on antiretroviral treatment. Eur J Clin Nutr 2003; 57(10): 1317-22.
[http://dx.doi.org/10.1038/sj.ejcn.1601694] [PMID: 14506495]
[26]
Tsukuda Y, Suda G, Tsunematsu S, et al. Anti-adipogenic and antiviral effects of l -carnitine on hepatitis C virus infection. J Med Virol 2017; 89(5): 857-66.
[http://dx.doi.org/10.1002/jmv.24692] [PMID: 27664407]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy